Resolution on amendment of the Articles of Association

The EGM resolved to amend §§ 4-5 of the Articles of Association whereby the share capital of the Company shall amount to not less than SEK 15,000,000 and not more than SEK 60,000,000 and the number of shares in the Company shall be not less than 500,000,000 and not more than 2,000,000,000 shares.

Approval of the resolution by the Board of Directors to issue new shares with preferential rights for the shareholders

The EGM resolved to approve the Board of Directors' resolution of 4 July 2022, to increase the Company's share capital by a maximum amount of SEK 21,459,961.80 through the issue of a maximum number of 715,332,060 ordinary shares.

The shareholders of the Company shall have preferential rights to subscribe for the new shares in relation the number of shares previously held, whereby one existing share entitles to subscribe for nine new ordinary shares. The record date for determining which shareholders shall be entitled to subscribe for new shares on a preferential basis shall be 5 August 2022.

Subscription for new shares based on subscription rights shall be made through payment in cash during the period from 9 August 2022 until and including 23 August 2022. Subscription without subscription rights shall be made through notice on special application form during the period from 9 August 2022 until and including 23 August 2022.

The subscription price is SEK 0.3 per share which in the case of full subscription provides issuing proceeds of up to approximately MSEK 215.

Resolution to implement an incentive scheme (LTIP 2022)

The EGM resolved to approve the Board of Director's proposal regarding a long-term incentive program 2022 (LTIP 2022) in accordance with items A, B and D.4 of the proposal.

Resolution in respect of authorisation for the Board of Directors to resolve to issue shares, warrants and/or convertible bonds

The EGM resolved to authorise the Board of Director's to resolve to increase share capital through the issue of new shares, warrants and/or convertibles.                                                             

Complete proposals regarding the EGM's decisions are available on IRRAS AB:s website www.irras.com.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

USA
Will Martin
President and CEO
ir@irras.com

Europe
Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on August 3, 2022, at 11.30 (CET).